{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:09:48Z","timestamp":1787162988826,"version":"build-2736575974"},"reference-count":76,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2023.2699","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T07:47:21Z","timestamp":1700034441000},"source":"Crossref","is-referenced-by-count":10,"title":["Pure testicular choriocarcinoma, a rare and highly malignant subtype with challenging treatment: A case report and review of the literature"],"prefix":"10.3892","volume":"20","author":[{"given":"Na","family":"Lei","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital. C. T.), Chengdu, Sichuan 610041, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital. C. T.), Chengdu, Sichuan 610041, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital. C. T.), Chengdu, Sichuan 610041, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Rong","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital. C. T.), Chengdu, Sichuan 610041, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"key":"key20240115110656_b1-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"key20240115110656_b2-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/PAS.0b013e3182a2926e","article-title":"Clinicopathologic analysis of choriocarcinoma as a pure or predominant component of germ cell tumor of the testis","volume":"38","author":"Alvarado-Cabrero","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"key20240115110656_b3-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.mcna.2017.10.003","article-title":"Testicular cancer: Epidemiology, diagnosis, and management","volume":"102","author":"Smith","year":"2018","journal-title":"Med Clin North Am"},{"key":"key20240115110656_b4-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/107327480401100605","article-title":"Pathology of germ cell tumors of the testis","volume":"11","author":"Sesterhenn","year":"2004","journal-title":"Cancer Control"},{"key":"key20240115110656_b5-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"key20240115110656_b6-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.juro.2014.06.039","article-title":"Choriocarcinoma of the Testis","volume":"192","author":"Humphrey","year":"2014","journal-title":"J Urol"},{"key":"key20240115110656_b7-MCO-20-1-02699","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00001703-199308000-00010","article-title":"Gestational and non-gestational trophoblastic neoplasms: New developments in DNA analysis, metabolic function, diagnosis and treatment","volume":"5","author":"Pattillo","year":"1993","journal-title":"Curr Opin Obstet Gynecol"},{"key":"key20240115110656_b8-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1365-2559.2000.00789.x","article-title":"Primary choriocarcinoma and human chorionic gonadotrophin-producing giant cell carcinoma of the lung: Are they independent entities?","volume":"36","author":"Ikura","year":"2000","journal-title":"Histopathology"},{"key":"key20240115110656_b9-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.humpath.2004.06.005","article-title":"Rectal adenocarcinoma with choriocarcinomatous differentiation: Clinical and genetic aspects","volume":"35","author":"Verbeek","year":"2004","journal-title":"Hum Pathol"},{"key":"key20240115110656_b10-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"874","DOI":"10.4143\/crt.2020.1066","article-title":"Clinical experience of male primary choriocarcinoma at the samsung medical center","volume":"53","author":"Ji","year":"2021","journal-title":"Cancer Res Treat"},{"key":"key20240115110656_b11-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1053\/j.semdp.2022.07.001","article-title":"Germ cell neoplasms of the testis: Update for 2022","volume":"40","author":"Iczkowski","year":"2023","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"key20240115110656_b12-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-014-0430-0","article-title":"Testicular choriocarcinoma: A rare variant that requires a unique treatment approach","volume":"17","author":"Reilley","year":"2015","journal-title":"Curr Oncol Rep"},{"issue":"103568","key":"key20240115110656_b13-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103568","article-title":"High dose chemotherapy followed by autologous hematopoietic stem cell transplantation for advanced germ cell tumors: State of the art and a single-center experience","volume":"169","author":"Pierantoni","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20240115110656_b14-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.urology.2018.12.025","article-title":"Germ cell testicular tumors-contemporary diagnosis, staging and management of localized and advanced disease","volume":"125","author":"Goldberg","year":"2019","journal-title":"Urology"},{"key":"key20240115110656_b15-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.humpath.2018.07.016","article-title":"Testicular germ cell tumors: Revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists","volume":"82","author":"Lobo","year":"2018","journal-title":"Hum Pathol"},{"key":"key20240115110656_b16-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/ENDO:19:1:3","article-title":"Hormones and human trophoblast differentiation: A review","volume":"19","author":"Malassin\u00e9","year":"2002","journal-title":"Endocrine"},{"key":"key20240115110656_b17-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2350\/16-09-1829-PER.1","article-title":"Perspectives in pediatric pathology, chapter 25. Testicular and paratesticular tumors in the pediatric age group","volume":"19","author":"Nistal","year":"2016","journal-title":"Pediatr Dev Pathol"},{"key":"key20240115110656_b18-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/s0022-5347(17)44095-x","article-title":"Metastatic pure choriocarcinoma of the testis in an elderly man","volume":"137","author":"Ramon y Cajal","year":"1987","journal-title":"J Urol"},{"key":"key20240115110656_b19-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ucl.2019.04.003","article-title":"Current management of disseminated germ cell tumors","volume":"46","author":"Lavoie","year":"2019","journal-title":"Urol Clin North Am"},{"key":"key20240115110656_b20-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/0090-4295(76)90374-5","article-title":"Metastases from testicular carcinoma. Study of 78 autopsied cases","volume":"8","author":"Johnson","year":"1976","journal-title":"Urology"},{"issue":"001754","key":"key20240115110656_b21-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.12890\/2020_001754","article-title":"Thyroid storm associated with testicular choriocarcinoma","volume":"7","author":"Mart\u00ednez-Gallegos","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"issue":"218","key":"key20240115110656_b22-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00218","article-title":"severe complications in testicular germ cell tumors: The choriocarcinoma syndrome","volume":"10","author":"Rejlekova","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"911879","key":"key20240115110656_b23-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.911879","article-title":"Factors associated with choriocarcinoma syndrome development in poor-risk patients with germ cell tumors","volume":"12","author":"Rejlekova","year":"2022","journal-title":"Front Oncol"},{"key":"key20240115110656_b24-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5489\/cuaj.7945","article-title":"Canadian Urological Association consensus guideline: Management of testicular germ cell cancer","volume":"16","author":"Hamilton","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"key20240115110656_b25-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/annonc\/mdp366","article-title":"High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors","volume":"21","author":"Lorch","year":"2010","journal-title":"Ann Oncol"},{"key":"key20240115110656_b26-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clgc.2023.01.004","article-title":"Maintenance oral etoposide after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors (mGCT)","volume":"21","author":"Taza","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"key20240115110656_b27-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/s0022-5347(17)40007-3","article-title":"Delay in diagnosis and survival in testicular cancer: Impact of effective therapy and changes during 18 years","volume":"143","author":"Moul","year":"1990","journal-title":"J Urol"},{"key":"key20240115110656_b28-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1002\/1097-0142(19900615)65:12<2681::aid-cncr2820651214>3.0.co;2-v","article-title":"Primary malignant extragonadal germ cell tumors. An analysis of the effect of the effect of radiotherapy","volume":"65","author":"Kersh","year":"1990","journal-title":"Cancer"},{"key":"key20240115110656_b29-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.prro.2017.01.004","article-title":"Stereotactic radiation therapy for residual chemorefractory primary mediastinal non-seminomatous germ cell tumor after surgical thoracotomy","volume":"7","author":"Laflamme","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"972","key":"key20240115110656_b30-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10050972","article-title":"Overcoming chemotherapy resistance in germ cell tumors","volume":"10","author":"Orszaghova","year":"2022","journal-title":"Biomedicines"},{"issue":"573977","key":"key20240115110656_b31-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.573977","article-title":"Immunotherapy in testicular germ cell tumors","volume":"10","author":"Kalavska","year":"2020","journal-title":"Front Oncol"},{"issue":"e12","key":"key20240115110656_b32-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2013.13","article-title":"Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer","volume":"15","author":"Koster","year":"2013","journal-title":"Expert Rev Mol Med"},{"issue":"102054","key":"key20240115110656_b33-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102054","article-title":"Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities","volume":"88","author":"de Vries","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"key20240115110656_b34-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.critrevonc.2019.09.005","article-title":"Targeted treatment approaches in refractory germ cell tumors","volume":"143","author":"Galvez-Carvajal","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20240115110656_b35-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1158\/1535-7163.MCT-19-0449","article-title":"Dual mTORC1\/2 inhibition sensitizes testicular cancer models to cisplatin treatment","volume":"19","author":"Rosas-Plaza","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"key20240115110656_b36-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1172\/JCI41939","article-title":"Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer","volume":"120","author":"Koster","year":"2010","journal-title":"J Clin Invest"},{"issue":"382","key":"key20240115110656_b37-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-382","article-title":"Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors","volume":"13","author":"Juliachs","year":"2013","journal-title":"BMC Cancer"},{"key":"key20240115110656_b38-MCO-20-1-02699","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1323::AID-CNCR15>3.0.CO;2-G","article-title":"Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease","volume":"85","author":"Fukuda","year":"1999","journal-title":"Cancer"},{"key":"key20240115110656_b39-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/COC.0b013e31827de90d","article-title":"Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors","volume":"37","author":"Jain","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"key20240115110656_b40-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/annonc\/mdv479","article-title":"Bevacizumab\/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors","volume":"26","author":"Nieto","year":"2015","journal-title":"Ann Oncol"},{"key":"key20240115110656_b41-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/jclinpath-2012-201088","article-title":"PARP expression in germ cell tumours","volume":"66","author":"Mego","year":"2013","journal-title":"J Clin Pathol"},{"issue":"S5058","key":"key20240115110656_b42-MCO-20-1-02699","article-title":"Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial","volume":"38 (15 suppl)","author":"De Giorgi","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20240115110656_b43-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s10637-021-01130-5","article-title":"Gemcitabine, carboplatin and veliparib in multiple relapsed\/refractory germ cell tumours: The GCT-SK-004 phase II trial","volume":"39","author":"Mego","year":"2021","journal-title":"Invest New Drugs"},{"key":"key20240115110656_b44-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/s0046-8177(96)90310-x","article-title":"CD30 expression in seminoma","volume":"27","author":"Hittmair","year":"1996","journal-title":"Hum Pathol"},{"key":"key20240115110656_b45-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1053\/j.semdp.2005.11.003","article-title":"The use of immunohistochemistry in the differential diagnosis of tumors of the testis and paratestis","volume":"22","author":"Emerson","year":"2005","journal-title":"Semin Diagn Pathol"},{"key":"key20240115110656_b46-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.juro.2013.04.057","article-title":"Persistent CD30 expression by embryonal carcinoma in the treatment time course: Prognostic significance of a worthwhile target for personalized treatment","volume":"190","author":"Giannatempo","year":"2013","journal-title":"J Urol"},{"key":"key20240115110656_b47-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1046\/j.1365-2559.2001.01226.x","article-title":"Loss of CD30 expression in metastatic embryonal carcinoma: The effects of chemotherapy?","volume":"39","author":"Berney","year":"2001","journal-title":"Histopathology"},{"key":"key20240115110656_b48-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clgc.2016.03.020","article-title":"Brentuximab vedotin in CD30-Expressing germ cell tumors after chemotherapy failure","volume":"14","author":"Necchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"key20240115110656_b49-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1634\/theoncologist.2017-0544","article-title":"Treatment of CD30-Expressing germ cell tumors and sex cord stromal tumors with brentuximab vedotin: Identification and report of seven cases","volume":"23","author":"Albany","year":"2018","journal-title":"Oncologist"},{"key":"key20240115110656_b50-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br J Cancer"},{"key":"key20240115110656_b51-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/annonc\/mdv574","article-title":"Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors","volume":"27","author":"Cierna","year":"2016","journal-title":"Ann Oncol"},{"issue":"1535","key":"key20240115110656_b52-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101535","article-title":"Detailed characterization of immune cell infiltrate and expression of immune checkpoint molecules PD-L1\/CTLA-4 and MMR proteins in testicular germ cell tumors disclose novel disease biomarkers","volume":"11","author":"Lobo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20240115110656_b53-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/ajcp\/aqz184","article-title":"Differences in PD-L1-Expressing macrophages and immune microenvironment in testicular germ cell tumors","volume":"153","author":"Sadigh","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"key20240115110656_b54-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/iju.14885","article-title":"Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors","volume":"29","author":"Kawahara","year":"2022","journal-title":"Int J Urol"},{"key":"key20240115110656_b55-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.clgc.2017.04.005","article-title":"Durable response to immune checkpoint blockade in a platinum-refractory patient with nonseminomatous germ cell tumor","volume":"15","author":"Chi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"6867","key":"key20240115110656_b56-MCO-20-1-02699","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2017.6867","article-title":"Novel therapies in platinum-refractory metastatic germ cell tumor: A case report with a focus on a PD-1 inhibitor","volume":"9","author":"Loh","year":"2017","journal-title":"Rare Tumors"},{"key":"key20240115110656_b57-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.21037\/tcr.2020.02.05","article-title":"A promising treatment option for refractory male primary choriocarcinoma: Report of two cases","volume":"9","author":"Han","year":"2020","journal-title":"Transl Cancer Res"},{"key":"key20240115110656_b58-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.01.033","article-title":"Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation","volume":"76","author":"Zschabitz","year":"2017","journal-title":"Eur J Cancer"},{"key":"key20240115110656_b59-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: A Hoosier Cancer Research Network Study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann Oncol"},{"key":"key20240115110656_b60-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/onco.13682","article-title":"Pembrolizumab in patients with advanced metastatic germ cell tumors","volume":"26","author":"Tsimberidou","year":"2021","journal-title":"Oncologist"},{"key":"key20240115110656_b61-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s10637-019-00805-4","article-title":"Phase II study of avelumab in multiple relapsed\/refractory germ cell cancer","volume":"37","author":"Mego","year":"2019","journal-title":"Invest New Drugs"},{"key":"key20240115110656_b62-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"key":"key20240115110656_b63-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.eururo.2018.09.010","article-title":"An open-label randomized phase 2 study of durvalumab alone or in combination with tremelimumab in patients with advanced germ cell tumors (APACHE): Results from the first planned interim analysis","volume":"75","author":"Necchi","year":"2019","journal-title":"Eur Urol"},{"key":"key20240115110656_b64-MCO-20-1-02699"},{"key":"key20240115110656_b65-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20240115110656_b66-MCO-20-1-02699","first-page":"1685","article-title":"Kit expression in male germ cell tumors","volume":"27 (3B)","author":"Nikolaou","year":"2007","journal-title":"Anticancer Res"},{"key":"key20240115110656_b67-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/annonc\/mdg244","article-title":"Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors","volume":"14","author":"Madani","year":"2003","journal-title":"Ann Oncol"},{"key":"key20240115110656_b68-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s12094-010-0532-6","article-title":"Expression of EGFR, HER-2\/neu and KIT in germ cell tumours","volume":"12","author":"Dur\u00e1n","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"key20240115110656_b69-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/01.coc.0000195086.47548.ef","article-title":"Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT","volume":"29","author":"Einhorn","year":"2006","journal-title":"Am J Clin Oncol"},{"issue":"2648","key":"key20240115110656_b70-MCO-20-1-02699","article-title":"Phase II multicenter study of imatinib in patients with chemorefractory germ cell tumors that express c-kit","volume":"67 (9 Suppl)","author":"Piulats","year":"2007","journal-title":"Cancer Res"},{"key":"key20240115110656_b71-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.88.15.6662","article-title":"Correlation between retinoblastoma gene expression and differentiation in human testicular tumors","volume":"88","author":"Strohmeyer","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240115110656_b72-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/cncr.29213","article-title":"Phase 2 trial of the cyclin-dependent kinase 4\/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"issue":"S517","key":"key20240115110656_b73-MCO-20-1-02699","article-title":"A phase II study of ribociclib in men with unresectable, incurable teratoma with recent progression","volume":"37 (7 suppl)","author":"Castellano","year":"2019","journal-title":"J Clin Oncol"},{"issue":"S882","key":"key20240115110656_b74-MCO-20-1-02699","article-title":"The anti-claudin 6 antibody, IMAB027, induces antibody-dependent cellular and complement-dependent cytotoxicity in claudin 6-expressing cancer cells","volume":"78 (13 suppl)","author":"T\u00fcreci","year":"2018","journal-title":"Cancer Res"},{"issue":"S1907","key":"key20240115110656_b75-MCO-20-1-02699","article-title":"Claudin 6 is a carcinoembryonic antigen with cancer stem cell marker features","volume":"78 (13_suppl)","author":"T\u00fcreci","year":"2018","journal-title":"Cancer Res"},{"key":"key20240115110656_b76-MCO-20-1-02699","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s10637-022-01276-w","article-title":"A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors","volume":"40","author":"Adra","year":"2022","journal-title":"Invest New Drugs"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:07:11Z","timestamp":1705291631000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2023.2699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,15]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2023.2699","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"article-number":"1"}}